1. Home
  2. COPR vs CRDF Comparison

COPR vs CRDF Comparison

Compare COPR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Copper Corporation Common Stock

COPR

Idaho Copper Corporation Common Stock

HOLD

Current Price

$1.18

Market Cap

60.1M

Sector

N/A

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COPR
CRDF
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.1M
67.1M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
COPR
CRDF
Price
$1.18
$0.87
Analyst Decision
Buy
Analyst Count
0
6
Target Price
★ $15.38
$6.28
AVG Volume (30 Days)
70.4K
★ 346.5K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ N/A
N/A
Revenue
★ $609,174.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.62
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$1.05
$0.71
52 Week High
$4.16
$3.31

Technical Indicators

Market Signals
Indicator
COPR
CRDF
Relative Strength Index (RSI) 22.37 50.36
Support Level N/A $0.88
Resistance Level $3.63 $1.13
Average True Range (ATR) 0.22 0.07
MACD 0.00 0.01
Stochastic Oscillator 12.37 73.92

Price Performance

Historical Comparison
COPR
CRDF

About COPR Idaho Copper Corporation Common Stock

Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: